ZSF1 rat as animal model for HFpEF: Development of reduced diastolic function and skeletal muscle dysfunction
Abstract Aims The prevalence of heart failure with preserved ejection fraction (HFpEF) is still increasing, and so far, no pharmaceutical treatment has proven to be effective. A key obstacle for testing new pharmaceutical substances is the availability of suitable animal models for HFpEF, which real...
Main Authors: | Antje Schauer, Runa Draskowski, Anett Jannasch, Virginia Kirchhoff, Keita Goto, Anita Männel, Peggy Barthel, Antje Augstein, Ephraim Winzer, Malte Tugtekin, Siegfried Labeit, Axel Linke, Volker Adams |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12915 |
Similar Items
-
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
by: Antje Schauer, et al.
Published: (2021-03-01) -
Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility
by: Volker Adams, et al.
Published: (2022-06-01) -
Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model
by: Ephraim B. Winzer, et al.
Published: (2022-09-01) -
Leucine Supplementation Improves Diastolic Function in HFpEF by HDAC4 Inhibition
by: Paula Ketilly Nascimento Alves, et al.
Published: (2023-11-01) -
Leucine Supplementation Prevents the Development of Skeletal Muscle Dysfunction in a Rat Model of HFpEF
by: Paula Ketilly Nascimento Alves, et al.
Published: (2024-03-01)